

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: BM2/21 - Bone Markers

Deadline: 29.10.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(431) Parathyroid hormone (PTH)					29							28	26	93%
Samples and groups	[pmol/L]													
Sample A		19,6	3,2	16	29							28	27	96%
(60) Roche		18,9	1,5	7,8	17	0	CVPG	19	0,44	23%	14,6	23,4	17	
(179) Siemens		21,5	1,1	4,9	6	0	CVPG	21,4	0,98	23%	16,4	26,4	6	
Other					6	0							5	
								3x 1, 2x 12, 1x 29						
Sample B		6,53	1,2	18	29							28	26	93%
(60) Roche		6,19	0,67	11	17	0	CVPG	6,22	0,19	23%	4,78	7,66	17	
(179) Siemens		7,31	0,36	4,9	6	0	CVPG	7,47	0,23	23%	5,75	9,19	6	
Other					6	1							5	
								3x 1, 2x 12, 1x 29						
(432) Collagen telopeptide CTx-beta					20							19	19	100%
Samples and groups	[ng/L]													
Sample A		654	53	8,1	20							19	19	100%
(60) Roche		658	49	7,5	19	0	CVPG	675	12	17%	560	790	19	
Other					1	0							0	
								1x 183						
Sample B		284	21	7,6	20							19	19	100%
(60) Roche		286	20	6,9	19	0	CVPG	292	4,7	17%	242	342	19	
Other					1	0							0	
								1x 183						
(433) P1NP					14							14	14	100%
Samples and groups	[µg/L]													
Sample A		198	17	8,4	14							14	14	100%
(60) Roche		198	17	8,4	14	0	CVPG	200	4,3	20%	160	240	14	
Sample B		29,9	1,7	5,7	14							14	14	100%
(60) Roche		29,9	1,7	5,7	14	0	CVPG	30,4	0,66	20%	24,3	36,5	14	
(434) Osteocalcin					20							19	18	95%
Samples and groups	[µg/L]													
Sample A		88,0	6,1	7,0	20							19	18	95%
(60) Roche		88,0	4,4	5,0	18	0	CVPG	90,1	1,3	13%	78,3	102	18	
Other					2	0							1	
								1x 24, 1x 164						
Sample B		18,3	1,2	6,6	20							19	18	95%
(60) Roche		18,5	1,2	6,3	18	0	CVPG	18,9	0,21	13%	16,4	21,4	18	
Other					2	0							1	
								1x 24, 1x 164						
(435) 25-hydroxyvitamin D					29							27	25	93%
Samples and groups	[nmol/L]													
Sample A		155	29	19	29							27	25	93%
(256) Roche (2)		163	20	12	20	0	CVPG	166	5,6	33%	111	221	20	
Other					9	0							7	
								4x 1, 1x 12, 1x 60, 1x 149, 1x 179, 1x 998						
Sample B		83,5	21	25	29							27	25	93%
(256) Roche (2)		90,5	12	14	20	0	CVPG	93,3	3,2	33%	62,5	125	20	
Other					9	0							7	
								4x 1, 1x 12, 1x 60, 1x 149, 1x 179, 1x 998						

st_kn_p

End of report

Printed: 09.11.2021